Biotech Values

[biotech jim]

Is it safe to assume that AZN/RIGL incorporated a radiographic study into the ongoing pivotal fostamatinib trials?

I have not been following RIGL closely for the past 2 years. But, I do know that Mike Weinblatt, MD and past president of the American College of Rheumatology, is an advisor for fostamatinib clinical trials. He is well-versed in the agency requirements as he has been involved in both TNF sequesterer trials and B-cell relevant RA studies (with abatacept).

So, I can only conclude that one of the registration studies will have a radiographic endpoint.